Alteração de sede deferida
#25.7
02/10/2026
RPI 2875
Application data
Number
112023026691Type
Filing
Publication
PCT
US2022073209 The application was filed at the INPI on 06/28/2022. It awaits formal examination and publication in the RPI gazette.
Latest action published by the INPI: 02/10/2026. We update with every new RPI gazette, published weekly.
Applicants
NEUROCRINE BIOSCIENCES INC.
US
Inventors
A. A. (pessoa física)
US
IPC Classification
Priority claims
US
63/216,875 · 06/30/2021
US
63/242,794 · 09/10/2021
US
63/276,079 · 11/05/2021
US
63/362,561 · 04/06/2022
Abstract
VALBENAZINA PARA USO NO TRATAMENTO COMPLEMENTAR DE ESQUIZOFRENIA. A presente invenção refere-se a métodos para o tratamento complementar de esquizofrenia usando um inibidor de isoforma transportadora de monoamina vesicular 2 (VMAT2). Em certas modalidades, o inibidor de VMAT2 é valbenazina ou um sal farmaceuticamente aceitável do mesmo.
Publications in the Brazilian Industrial Property Gazette (RPI).
#25.7
02/10/2026
RPI 2875
#1.3
03/05/2024
RPI 2774
#1.1
12/26/2023
RPI 2764
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.